黄忠
     

  • 个人简历

    复旦特聘研究员，博士生导师。

    个人邮箱：  huangzhong@fudan.edu.cn

    1997年获中国农业大学博⼠学位。1998-2002年，美国康奈尔大学Boyce Thompson研究所，博士后。2002-2008年，美国亚利桑那州立大学，先后任职高级研究助理和研究助理教授。2009-2022年，中国科学院上海巴斯德研究所，担任课题组长（PI）、研究员、博士生导师。2023年2月加入上海市重大传染病和生物安全研究院。

  • 研究方向

    黄忠课题组面向国家重大需求、面向人民生命健康，长期致力于创新疫苗和免疫治疗策略的应用基础研究。现阶段的研究工作聚焦于基于病毒样颗粒（Virus-Like Particle，VLP）的新型疫苗研发，主要方向包括： 

    l  设计、表达和临床前测试VLP作为疫苗和药物载体的有效性； 

    l  利用结构生物学手段解析VLP高分辨率结构，阐明VLP组装的结构基础；

    l  探究免疫系统摄取、加工和递呈病毒样颗粒的机制； 

    l  优化重组表达系统，实现VLP疫苗的高效生产。


  • 重要学术贡献

    黄忠研究员在抗病毒基因工程疫苗和抗体研究领域取得诸多创新成果，在Nature、Nature Communications、Science Advances、Cell Discovery、Gut、PLOS Pathogens等国际知名学术刊物上发表通讯作者（含共同通讯）论文逾60篇；申请专利20 余项，其中10 项已获授权；主持研发的4项成果实现转移转化，其中1个创新疫苗品种（四价重组诺如病毒疫苗）已进入临床三期试验。

     

    发表文章（2000年-至今）

    l  Hong Q #, Wang S #, Wang X, Han W, Chen T, Liu Y, Cheng F, Qin S, Zhao S, Liu Q *, Cong Y*, Huang Z *. Vaccine potency and structure of yeast-produced polio type 2 stabilized virus-like particles. Vaccines. 2024, 12(9):1077.

    l  Wang T #, Wang C #, Pang L, Zhang Y, Wang S, Liang X*, Huang Z*. Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles. Emerging Microbes & Infections 2024, 13:2337665.

    l  Zhang C #, Liu C #, Shi J #, Wang Y, Xu C, Ye X, Liu Q, Li X, Qiao W, Yin Y, Cong Y*, Huang Z*. Molecular Mechanism of antibody neutralization of coxsackievirus A16. Nature Communications 2022, 13:7854.

    l  Zang J #, Yin Y #, Xu S, Qiao W, Liu Q, Lavillette D, Zhang C*, Wang H*, Huang Z*. Neutralizing potency of prototype and Omicron RBD mRNA vaccines against Omicron variant. Frontiers in Immunology 2022, 13:908478.

    l  Zhou P, Wang X, Xing M, Yang X, Wu M, Shi H, Zhu C, Wang X, Guo Y, Tang S, Huang Z*, Zhou D*. Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy. Molecular Therapy Oncolytics. 2022, 25:236-248.

    l  Hong Q #, Han W #, Li J #, Xu S #, Wang Y #, Xu C, Li Z, Wang Y*, Zhang C*, Huang Z*, Cong Y*. Molecular basis of receptor binding and antibody neutralization of Omicron. Nature 2022, 604(7906):546-552.

    l  Wang Y#, Liu C#, Zhang C#, Wang Y#, Hong Q#, Xu S, Li Z, Yang Y, Huang Z*, Cong Y*. Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. Nature Communications2022, 13(1):871.

     l  Xu S #, Wang Y-F #, Wang Y-X#, Zhang C #, Hong Q #, Gu C #, Xu R #, Wang T, Yang Y, Zang J, Zhou Y, Li Z, Liu Q, Zhou B, Bai L, Zhu Y, Deng Q, Wang H, Lavillette D, Wong G *, Xie Y*, Cong Y*, Huang Z*. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein. Emerging Microbes & Infections 2022, 11(1):351-367

    l  Qiao W, Wang S, Zhang C*, Huang Z*. A split NanoLuc complementation-based human norovirus-like particle entry assay facilitates evaluation of anti-norovirus antibodies in live cells. Antiviral Research 2022, 197:105231

    l  Wang Y #, Xu C#, Wang Y #, Hong Q #, Zhang C #, Li Z, Xu S, Zuo Q, Liu C, Huang Z*, Cong Y*. Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM. Nature Communications 2021, 12:7345.

    l  Yi Y#, Wang S#, Wang X#, Xiong P, Liu Q, Zhang C*, Yin F*, Huang Z*. Identification of human norovirus GII.3 blockade antibody epitopes. Viruses. 2021, 13:2058.

    l  Zang J#, Zhu Y#, Zhou Y#, Gu C#, Yi Y#, Wang S, Xu S, Hu G, Du S, Yin Y, Wang Y, Yang Y, Zhang X, Wang H, Yin F, Zhang C*, Deng Q*, Xie Y*, Huang Z*. Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. Cell Discovery 2021, 7(1):71.

    l  Yang Y#, Zang J#, Xu S, Zhang X, Yuan S, Wang H, Lavillette D, Zhang C*, Huang Z*. (2021) Elicitation of broadly neutralizing antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 variants by three prototype strain-derived recombinant protein vaccines. Viruses. 2021, 13(8):1421.

    l  Zhang C#, Xu C#, Dai W#, Wang Y, Liu Z, Zhang X, Wang X, Wang H, Gong S*, Cong Y*, Huang Z*. (2021) Functional and structural characterization of a two-MAb cocktail for delayed treatment of enterovirus D68 infections. Nature Communications. 2021, 12(1):2904.

    l  Yi Y#, Wang X#, Wang S#, Xiong P, Liu Q, Zhang C*, Yin F*, Huang Z*. Identification of a blockade epitope of human norovirus GII.17. Emerging Microbes & Infections 2021, 10(1):954-963.

    l  Yang R, Liu Q, Pang W, Gao F, Liang H, Zhang W, Lin Y, Li M, Liu Z, Gao GF, Zhang L, Xiao H, Zheng Y, Huang Z*, Jin X*. Two immunogenic recombinant protein vaccine candidates showed disparate protective efficacy against Zika virus infection in rhesus macaques. Vaccine. 2021, 39(6):915-925.

    l  Zhang C#, Wang Y #, Zhu Y #, Liu C #, Gu C #, Xu S #, Wang Y, Zhou Y, Wang Y, Han W, Hong X, Yang Y, Zhang X, Wang T, Xu C, Hong Q, Wang S, Zhao Q, Qiao W, Zang J, Kong L, Wang F, Wang H, Qi D, Lavillette D, Tang H, Deng Q*, Xie Y*, Cong Y*, Huang Z*. (2021) Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Nature Communications. 2021, 12(1):264.

    l  Xu C#, Wang Y #, Liu C #, Zhang C #, Han W #, Hong X, Wang Y, Hong Q, Wang S, Zhao Q, Wang Y, Yang Y, Chen K, Zheng W, Kong L, Wang F, Zuo Q, Huang Z*, Cong Y*.  Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Science Advances2021, 7(1):eabe5575.

    l  Zang J #, Gu C #, Zhou B #, Zhang C #, Yang Y #, Xu S, Bai L, Zhang R, Deng Q, Yuan Z, Tang H, Qu D, Lavillette D*, Xie Y*, Huang Z*. (2020) Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement. Cell Discovery 2020, 6:61.

    l  Qu P #, Zhang C #, Li M #, Ma W, Xiong P, Liu Q, Zou G, Lavillette D, Yin F*, Jin X*, Huang Z*. (2020) A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein. Cell Discovery 2020, 6:5.

    l  Yan Y #, Wang X #, Lou P, Hu Z, Qu P, Li D, Li Q, Xu Y, Niu J, He Y, Zhong J *, Huang Z* (2020) A nanoparticle-based hepatitis C virus vaccine with enhanced potency. Journal of Infectious Diseases2020, 221(8):1304-1314.


  • 荣誉与奖励

    2010 中科院“百人计划”

    2010 赛诺菲—中国科学院上海生命科学研究院优秀青年人才

    2014 中国科学院大学“朱李月华”优秀教师奖

    2015 上海市“优秀技术带头人”计划

    2016 中国科学院“王宽诚率先人才”计划

    2017 上海市科技系统“先进工作者”

    2019 “上海市五一劳动奖章”

    2019 中科院年度先锋人物提名人选

    2020 中国科学院“优秀共产党员”

    2020 上海市“先进工作者